Abstract
ABSTRACT This study aimed to reveal the effects of the COVID-19 pandemic on neuromotor development in infants (aged 6–24 months). A total of 75 infants were included in this cross-sectional observational study. Neuromotor development was assessed using the Alberta Infant Motor Scale (AIMS) and the Denver Developmental Screening Test II (DDST II). The AIMS results showed that 14.7% were classified as abnormal, 10.6% as suspicious, and 74.7% as normal. The DDST II results showed that 14.7% of the participants were classified as suspicious, 13.3% as abnormal, and 72% as normal. This study found that 25% of infants aged 6–24 months who experienced the COVID-19 pandemic exhibited questionable or abnormal neurological development. This reveals the negative impact of the pandemic on neuromotor development. Delays were observed more frequently in fine and gross motor areas. Trial registration: ClinicalTrials.gov identifier: NCT05778357.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
